An argument for broad use of high efficacy treatments in early multiple sclerosis

Abstract

Two different treatment paradigms are most often used in multiple sclerosis (MS). An escalation or induction approach is considered when treating a patient early in the disease course. An escalator prioritizes safety, whereas an inducer would favor efficacy. Our understanding of MS pathophysiology has evolved with novel in vivo and in vitro observations. The treatment landscape has also shifted significantly with the approval of over 10 new medications over the past decade alone. Here, we re-examine the treatment approach in light of these recent developments. We believe that recent work suggests that early prediction of the disease course is fraught, the amount of damage to the brain that MS causes is underappreciated, and its impact on patient function oftentimes is underestimated. These concerns, coupled with the recent availability of agents that allow a better therapeutic effect without compromising safety, lead us to believe that initiating higher efficacy treatments early is the best way to achieve the best possible long-term outcomes for people with MS. Multiple sclerosis following collection(s):This article, along with others on similar topics, appears in the Permissions & Licensing http://nn.neurology.org/misc/about.xhtml#permissions its entirety can be found online at: Information about reproducing this article in parts (figures,tables) or in Reprints http://nn.neurology.org/misc/addir.xhtml#reprintsus Information about ordering reprints can be found online: Academy of Neurology.. All rights reserved. Online

Assessing Pharmacists’ Preferences towards Efficacy Attributes of Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis

“…In addition, there may be other uncollected pharmacist characteristics that could explain differences in terms of preference for DMT options. Another limitation is the lack of analysis of different treatment frameworks (escalation versus highly effective treatment early approach) in our study [42].…”

A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20—Yet Progress Continues

“…The odds of achieving NEDA-3 (defined as absence of relapses, disability worsening, and MRI activity) was 3-fold higher at the first year and even 14-fold higher at the second year of treatment [55]. These data emphazise that early high efficacy treatment is necessary in order to achieve the best possible long-term outcome for MS patients [56].…”

Treatment strategies for multiple sclerosis - escalation and induction therapies

“…Niekorzystnie rokują: późniejszy wiek zachorowania, wysoki wskaźnik rzutów w pierwszych latach choroby czy obecność nasilonych zmian demielinizacyjnych w badaniu MRI. Cięższy przebieg choroby obserwowany jest u mężczyzn, jednak zarówno mężczyźni, jak i kobiety osiągają stopień niepełnosprawności uniemożliwiający samodzielne poruszanie się w podobnym wieku [46,47]. Strategię indukcyjną należy rozważyć u pacjentów z postacią RRSM w wieku poniżej 40 lat z wysoką aktywnością choroby stwierdzoną zarówno klinicznie, jak i w badaniach MRI.…”